Prevalence of insulin resistance and metabolic syndrome in patients with gouty arthritis
- 284 Downloads
The study was performed to confirm the high prevalence of metabolic syndrome in gouty patients and to define the relationship between insulin resistance and gouty arthritis. We recruited 83 patients with gouty arthritis and checked clinical factors according to the diagnostic criteria of metabolic syndrome from the ATP III guidelines and WHO Asia-Pacific obesity criteria recommendations. We also assessed the clinical characteristics of subjects and homeostasis model assessment of insulin resistance (HOMA-IR) and compared with previous study groups as controls. The prevalence of metabolic syndrome in patients with gout was 30.1% according to ATP III criteria and 50.6% with WHO Asia-Pacific adjustment and is significantly higher than the previous control study groups (ATP III: 5.2, 10.6%, WHO Asia-Pacific adjustment: 9.8, 13.9%). The mean value of HOMA-IR in patients with gout was 2.63 ± 1.36 and is significantly higher than control study (1.91 ± 1.01, P < 0.05). There were significant correlations between 24-h urinary uric acid excretion and waist circumference (r 2 = 0.225, P = 0.049), fasting insulin (r 2 = 0.241, P = 0.035), and insulin resistance (HOMA-IR) (r 2 = 0.271, P = 0.017). There were significant correlations between insulin resistance and waist circumference (r 2 = 0.341, P < 0.01), BMI (r 2 = 0.390, P < 0.01). The value of HOMA-IR (insulin resistance) and the prevalence of metabolic syndrome in patients with gout are significantly higher than normal healthy control groups. The hyperuricemia in gout might be caused by the increased adiposity associated with insulin resistance.
KeywordsGout Insulin resistance Metabolic syndrome
This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A084144).
- 3.Choi HK, Mount DB, Reginato AM; American College of Physicians; American Physiological Society (2005) Pathogenesis of gout. Ann Intern Med 143(7):499–516Google Scholar
- 7.Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Song GG (2004) Prevalence of the metabolic syndrome in patients with gout. J Korean Rheum Assoc 11(4):349–357Google Scholar
- 15.Park SH, Lee WY, Kim SW (2003) The relative risks of the metabolic syndrome defined by adult treatment panel 3 according to insulin resistance in Korean population. Korean J Med 64(5):552–561Google Scholar
- 16.National Institutes of Health (2001) Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01-3670. National Institutes of Health, BethesdaGoogle Scholar
- 17.Steering Committee of the WHO Western Pacific Region, IASO & IOTF (2000) The Asia-Pacific perspective: Redefining obesity and its treatment. Steering Committee of the WHO Western Pacific Region, IASO & IOTF, AustraliaGoogle Scholar
- 18.Park JS, Park HD, Yun JW, Jung CH, Lee WY, Kim SW (2002) Prevalence of the metabolic syndrome as defined by NCEP—ATPIII among the urban Korean population. Korean J Med 63(3):290–299Google Scholar
- 22.Kim EH, Jeon KM, Park KW, Kim HJ, Ahn JK, Jeon CH, Cha HS, Koh EM (2004) The prevalence of gout among hyperuricemic population. J Korean Rheum Assoc 11(1):7–13Google Scholar
- 29.Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K (2003) Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 18(6):523–530Google Scholar
- 33.Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J (2000) Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59(7):539–543PubMedCrossRefGoogle Scholar